Non-Invasive Evaluation and Early Treatment of Heart Failure Patients

  • M. Scherillo
  • F. Scotto di Uccio
  • F. Vigorito
  • D. Miceli
  • M. G. Tesorio
  • V. Monda
  • R. Calabrò
Conference paper


The effects of the growing spreading of heart failure (HF) in Italy can be described on the basis of data from the Italian National Health Care System ( relating to the number of patients discharged from Italian hospitals with the main diagnosis of HF (DRG 127) in the last 5 years (Fig. 1). From 86 235 patients discharged in 1995, the number reached 170 972 discharged with DRG 127 in 1999. In 5 years, the number of patients with HF discharged from Italian hospitals has nearly doubled, with an estimated global cost of about € 500 million per year.


Natriuretic Peptide Heart Failure Patient Brain Natriuretic Peptide Atrial Natriuretic Peptide Left Ventricular Systolic Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Scherillo M (2001) Oral presentation. XXXI National Congress of Italian Association Hospital Cardiologists (ANMCO), 16–19 May, Florence, ItalyGoogle Scholar
  2. 2.
    Hoes AW, Mosterd A, Grohbee DE (1998) An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 19[Suppl L]:L2–9PubMedGoogle Scholar
  3. 3.
    Cowie MR, Mosterd A, Wood DA et al (1997) The epidemiology of heart failure. Eur Heart J 18: 208–225PubMedCrossRefGoogle Scholar
  4. 4.
    Yamani M, Massie BM (1993) Congestive heart failure: insights from epidemiology, implications for treatment. Mayo Clinic Proc 68:1214–1218CrossRefGoogle Scholar
  5. 5.
    McKelvie R S, Benedict C R, Yusuf S (1999) Evidence based cardiology. Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. Br Med J 318:1400–1402CrossRefGoogle Scholar
  6. 6.
    Lauer MS, Evans JC, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham heart study). Am J Cardiol 70:1180–1184PubMedCrossRefGoogle Scholar
  7. 7.
    McMurray JJ, Petric MC, Murdock DR, Davie AP (1998) Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 19[Suppl P]:P 9–16CrossRefGoogle Scholar
  8. 8.
    Mosterd A, De Bruijine MC, Hoes AW, Deckers JW, Hofman A, Grobbee DE (1997) Usefulness of echocardiography in detecting left ventricular dysfunction in population based studies (the Rotterdam study). Am J Cardiol 79:103–104PubMedCrossRefGoogle Scholar
  9. 9.
    McDonagh T, Morrison CE, Lawrence A et al (1997) Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350:829–833PubMedCrossRefGoogle Scholar
  10. 10.
    Cleland JGF (1997) Screening for left ventricular dysfunction and heart failure: should it be done and if so how? Dis Manag Health Outcomes 1:169–84CrossRefGoogle Scholar
  11. 11.
    Cleland JGF, Khand A, Clark A (2001) The heart failure epidemic: exactly how big is it? Eur Heart J 22:623–626PubMedCrossRefGoogle Scholar
  12. 12.
    Kober L, Torp-Pedersen C, Carlsen JE et al (1995) A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670–1676PubMedCrossRefGoogle Scholar
  13. 13.
    De Vita C et al (1994) GISSI-3 Effects of lisinopril and transdermal glyceryl binitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115–1122Google Scholar
  14. 14.
    Kannel WB et al (1979) Prognosis after initial myocardial infarction: the Framinghan study. Am J Cardiol 44:53–59PubMedCrossRefGoogle Scholar
  15. 15.
    McKelvie RS, Benedict CR, Yusuf S (1998) Prevention of congestive heart failure and treatment of asymptomatic left ventricular dysfunction. In: Yusuf S, Cairns JA, Camm AJ, Fallen EI, Gersh BJ (eds) Evidence based cardiology. Br Med Publishing Group, London, pp 703–721Google Scholar
  16. 16.
    Shindler JM, Kostis JB, Yusuf S et al (1996) Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials ad registry. Am J Cardiol 77:1017–1020PubMedCrossRefGoogle Scholar
  17. 17.
    Gerstein HC, FeMann J, Zinman B et al (1997) Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and non-diabetic patients. Circulation 96 [Suppl 81:1225Google Scholar
  18. 18.
    Psaty BM, Smith NL, Siscovick DS et al (1997) Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277:739–745PubMedCrossRefGoogle Scholar
  19. 19.
    Kjekshus J, Pedersen TR, Olsson AG, Faegeman O, Pyorala K, on behalf of the 4S Study Group (1997) The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Failure 3:249–254Google Scholar
  20. 20.
    Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur Heart J 16: 741Google Scholar
  21. 21.
    Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in heart failure. JAMA 261:884–888PubMedCrossRefGoogle Scholar
  22. 22.
    Davie AP, Francis CM, Love MP et al (1996) Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J 312: 222CrossRefGoogle Scholar
  23. 23.
    Senni M, Rodeheffer RJ, Triboulloy CM et al (1999) Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol 33:171–173CrossRefGoogle Scholar
  24. 24.
    Quiñones MA, Greenberg BH, Koplen HA et al (2000) Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. J Am Coll Cardiol 35–5:1237–1244PubMedCrossRefGoogle Scholar
  25. 25.
    Mukherjee SK, Jaffe CC (1995) Left ventricular mass estimation by echocardiography: is it clinically useful? Echocardiography 12:185–193PubMedCrossRefGoogle Scholar
  26. 26.
    Hobbs FDR, Jones MI, Allan TF, Tobias R (2000) European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Euro Heart J 21:1877–1887CrossRefGoogle Scholar
  27. 27.
    Francis CM, Caruana L, Kearney P et al (1995) Open access echocardiography in management of heart failure in the community Br Med J 310:634–636CrossRefGoogle Scholar
  28. 28.
    Fox KF, Cowie MR, Wood DA, Coats AJS, Poole-Wilson PA, Sutton C (2000) A rapid access heart failure clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 4:423–429CrossRefGoogle Scholar
  29. 29.
    Phillips PA, Sasadeus J, Hodsman GP et al (1989) Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptochinase. Br Heart J 61:139–143PubMedCrossRefGoogle Scholar
  30. 30.
    Mukoyama M, Nakao K, Hosoda K et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 87:1402–1414PubMedCrossRefGoogle Scholar
  31. 31.
    Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides in mechanisms of disease. N Engl J Med 339:321–328PubMedCrossRefGoogle Scholar
  32. 32.
    Khono M, Yokokawa K, Yasunari K et al (1997) Changes in plasma natriuretic peptide concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy. Int J Clin Pharmacol Ther 35: 38–42Google Scholar
  33. 33.
    Arad M, Elazar E, Shotan A et al (1996) Brain and atrial natriuretic peptides in patients with ischemic disease with and without heart failure. Cardiology 87:12–17PubMedCrossRefGoogle Scholar
  34. 34.
    Masson S, Gorini M, Salio M, Lucci D, Latini R, Maggioni AP on behalf of the IN-CHF Investigators (2000) Clinical correlates of elevated plasma natriuretic peptides and Big-endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure(IN-CHF) registry. Ital Heart J 4:282–288Google Scholar
  35. 35.
    Valli N, Georges A, Corcuff J, Barat J, Bordenave L (2001) Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data. Clin Chim Acta 306:19–26PubMedCrossRefGoogle Scholar
  36. 36.
    Mallamaci F, Zoccali C, Tripepi G et al (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59:1599–1566CrossRefGoogle Scholar
  37. 37.
    Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM (2000) Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 6:194–200PubMedCrossRefGoogle Scholar
  38. 38.
    McDonagh TA (2000) Asymptomatic left ventricular dysfunction in the community. Curr Cardiol Rep 2:470–474PubMedCrossRefGoogle Scholar
  39. 39.
    Suzuki T, Yamaoki K, Nakajima O et al (2000) Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J 41:205–214PubMedCrossRefGoogle Scholar
  40. 40.
    Tamura K, Takahashi N, Nakatani Y, Onishi S, Iwasaka T (2001) Prognostic impact of plasma brain natriuretic peptide for cardiac events in elderly patients with congestive heart failure. Gerontology 47:46–51PubMedCrossRefGoogle Scholar
  41. 41.
    Maisel AS, Koon J, Krishnaswamy P et al (2001) Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141:367–374PubMedCrossRefGoogle Scholar
  42. 42.
    Cheng V, Kazanagra R, Garcia A et al (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure. Pilot study. J Am Coll Cardiol 37:386–391PubMedCrossRefGoogle Scholar
  43. 43.
    Bettencourt P, Ferreira A, Dias P et al (2000) Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 6:306–313PubMedCrossRefGoogle Scholar
  44. 44.
    Tsutamoto T, Wada A, Maeda K et al (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37:1228–1233PubMedCrossRefGoogle Scholar
  45. 45.
    Okumura H, Iuchi K, Yoshida T et al (2000) Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104:158–163PubMedCrossRefGoogle Scholar
  46. 46.
    Tsutamoto T, Wada A, Maeda K et al (1997) Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 134:910–916PubMedCrossRefGoogle Scholar
  47. 47.
    Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRefGoogle Scholar
  48. 48.
    Dao Q, Krishnaswamy P, Kazanegra R et al (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37:379–385PubMedCrossRefGoogle Scholar
  49. 49.
    Kazanegra R, Cheng V, Garcia A et al (2001) A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7:21–29PubMedCrossRefGoogle Scholar
  50. 50.
    Arakawa N, Nakamura M, Aoki H, Hiramori K (1996) Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 27:1656–1661PubMedCrossRefGoogle Scholar
  51. 51.
    Richards AM, Nicholls MG, Yandle TG et al (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurhormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921–1929PubMedCrossRefGoogle Scholar
  52. 52.
    Richards AM, Doughty R, Nicholls MG et al (1999) Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99:786–792PubMedCrossRefGoogle Scholar
  53. 53.
    Kawai K, Hata K, Takahoka H, Kawai H, Yokoyama M (2001) Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during (3-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141:925–932PubMedCrossRefGoogle Scholar
  54. 54.
    Cowie MR, Struthers AD, Wood DA et al (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350:1349–1353PubMedCrossRefGoogle Scholar
  55. 55.
    Bettencourt P, Ferreira A, Dias P, Castro A, Martins L, Cerqueira-Gomes M (2000) Evaluation of brain natrurietic peptide in the diagnosis of heart failure. Cardiology 93:19–25PubMedCrossRefGoogle Scholar
  56. 56.
    McDonald K, Ledwidge M, Cahill J et al (2001) Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. Eur J Heart Fail 3:209–215PubMedCrossRefGoogle Scholar
  57. 57.
    Pfeffer MA, Braunwald E, Moyè LA et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677PubMedCrossRefGoogle Scholar
  58. 58.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–828Google Scholar
  59. 59.
    The SOLVD Investigators (1992) Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691CrossRefGoogle Scholar
  60. 60.
    The CAPRICORN Investigators (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • M. Scherillo
    • 1
  • F. Scotto di Uccio
    • 2
  • F. Vigorito
    • 2
  • D. Miceli
    • 2
  • M. G. Tesorio
    • 3
  • V. Monda
    • 2
  • R. Calabrò
    • 3
  1. 1.Cardiologia Interventistica e UTICA.O. Rummo, BeneventoItaly
  2. 2.Dipartimento di CardiologiaAzienda Ospedaliera MonaldiNaplesItaly
  3. 3.Cattedra di CardiologiaSeconda Università di NapoliNaplesItaly

Personalised recommendations